Clin2
NCT05653193Possibly a fitActive, not recruiting

Interferon-gamma added to antifungals for chronic lung fungus

Chronic Pulmonary AspergillosisAspergillosis

Treatments studied

Part of Infections clinical trials.

This study tests whether adding interferon-gamma injections to standard antifungal treatment helps people with chronic pulmonary aspergillosis (CPA). Because it’s a feasibility study, the main goal is to see if the added treatment can be given safely and whether visits and measurements work smoothly.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
50 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have a diagnosis of chronic pulmonary aspergillosis (CPA).
  • You started antifungal treatment for CPA within the last 8 weeks, and you did not take CPA antifungals in the 8 weeks before starting.
  • You can provide a chest CT scan from within the last 6 months.
  • If you could become pregnant, you agree to a pregnancy test and use very effective contraception.
  • You must be able to consent and understand the study enough to give consent.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT03656081Recruiting· Phase 3
Treating chronic lung Aspergillus with inhaled and oral antifungals

This study tests whether a combination of inhaled liposomal amphotericin B (Ambisome) plus itraconazole works better for chronic pulmonary aspergillosis (CPA). It may help control long-term Aspergillus lung infection and symptoms.

Poitiers
NCT05444946Recruiting
Itraconazole alone versus with steroid pills for Aspergillus lung overlap

This trial compares itraconazole taken by mouth alone versus itraconazole plus steroid pills in people who have a mix of two Aspergillus lung conditions. It aims to see which approach works better to control symptoms and lung changes caused by Aspergillus infection.

Chandigarh, Chandigarh
NCT07530263Not yet recruiting· Phase 1
How inhaled antifungal medication deposits in lungs

This research study tracks how a inhaled antifungal medicine (amphotericin B in a special lipid form) deposits and distributes in the lungs of people with chronic pulmonary aspergillosis—a long-term fungal lung infection. The goal is to understand if this inhaled approach can effectively treat this condition.

Nijmegen
NCT06447402Recruiting· Phase 3
Inhaled Amphotericin B for Chronic Aspergillosis Maintenance

This study compares two inhaled treatments (amphotericin B vs. saline) to see which one works better as maintenance therapy for people with chronic pulmonary aspergillosis. It aims to find a convenient way to keep the infection under control after initial treatment.

Chandigarh
NCT06885905Recruiting
Impact of lung infection on health and well-being

This study looks at how chronic pulmonary aspergillosis (a long-term lung infection) affects your daily life, health, and overall well-being. By joining, you'll help researchers understand what it's like to live with this condition.

Dundee
NCT05860387Recruiting
Testing faster diagnosis of serious lung fungal infection

This study aims to detect invasive lung aspergillosis earlier by testing samples from your lungs and measuring specific lab markers. It may help doctors start the right antifungal treatment sooner when the infection is suspected.

Havířov, Moravian-Silesian Region

Hear when a new Chronic Pulmonary Aspergillosis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.